Innovation Drug Access in China: Three NMPA Approvals, Reviewed in October 2026

Direct answer. As of 6 October 2026, an NMPA marketing authorisation in mainland China is the start of access, not the end of it. Three decisions illustrate three different routes. Satricabtagene autoleucel (satri-cel; development code CT041; 舒瑞基奥仑赛注射液; trade name 恺力美) was approved in June 2026 for a defined population with advanced gastric or gastroesophageal-junction adenocarcinoma. Pirtobrutinib (Jaypirca) had its chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL) label expanded on 28 September 2026 to monotherapy across lines of therapy. Shanghai Livzon's 11.25 mg leuprorelin acetate microsphere, a three-month strength, was added by a supplementary approval announced on 30 September 2026.

In this article, access means the full route from regulatory authorisation to a patient's receipt of treatment: approval status, label eligibility, hospital availability, payment and continuity of care. NMPA approval does not, by itself, establish National Reimbursement Drug List coverage, nationwide hospital availability, or what an individual patient will pay. Where one of these products already has a reimbursement listing, that listing still has to be confirmed for the strength, the hospital and the visit.

Last reviewed: 6 October 2026. Jurisdiction: mainland China. Regulatory authority: National Medical Products Administration (NMPA, 国家药品监督管理局).

Key facts

Entity	NMPA development	Date	Precise approved population or use
Satricabtagene autoleucel injection; satri-cel; CT041; 舒瑞基奥仑赛注射液; 恺力美	Marketing approval through the priority review pathway	June 2026, reported on 23 June 2026	Advanced gastric or gastroesophageal-junction adenocarcinoma that is CLDN18.2-positive and HER2-negative, after at least second-line therapy has failed
Pirtobrutinib tablets; Jaypirca; 50 mg and 100 mg	Expanded CLL/SLL indication	28 September 2026	Monotherapy for adults with CLL/SLL across all lines of therapy, with or without prior covalent BTK inhibitor treatment
Leuprorelin acetate microspheres for injection, 11.25 mg; 注射用醋酸亮丙瑞林微球	Supplementary approval adding this strength; notice 2026B06648; 国药准字H20269239, valid to 27 April 2029	Announced 30 September 2026	Premenopausal breast cancer, prostate cancer and central precocious puberty; subcutaneous injection every 12 weeks

Date clarification. The marketing approval of satricabtagene autoleucel was granted in June 2026. It is not a September or October approval. The late-September developments were the Jaypirca label expansion and the supplementary approval of the 11.25 mg leuprorelin microsphere.

Satricabtagene autoleucel: a CAR-T approval with a narrow solid-tumour label

Satricabtagene autoleucel injection is an autologous chimeric antigen receptor T-cell (CAR-T) therapy directed at Claudin 18.2 (CLDN18.2). The 23 June 2026 report republished by the Shanghai Science and Technology Commission says the NMPA approved it through the priority review pathway for the population in the table above. The same report describes it as the first CAR-T cell therapy product approved for a solid tumour. That description belongs to the report. It is not a licence to present the product as treatment for every solid tumour.

The applicant named in that report is 恺兴生命科技（上海）有限公司, the Shanghai company of CARsgen Therapeutics (科济药业). The label boundary is the part that matters for a patient. The approved population must have advanced gastric or gastroesophageal-junction adenocarcinoma, the tumour must be CLDN18.2-positive and HER2-negative, and at least second-line therapy must have failed. The approval should not be read as covering every gastric cancer, every solid tumour, or any use outside that label.

Gastric cancer explains the disease, staging and the treatments that usually come before a later-line option. Gastroscopy in China for international patients explains the endoscopy that produces the tissue diagnosis. Neither page decides CAR-T eligibility.

Access to an autologous CAR-T therapy depends on more than the label. It requires biomarker testing, a treatment service equipped for this product, leukapheresis and manufacturing scheduling, inpatient monitoring and the capacity to manage toxicities, product supply, and a payment arrangement. For this kind of therapy, approval opens a pathway. It does not complete it, and it does not tell a family which service can accept the case on a given date.

Pirtobrutinib: a CLL/SLL label expanded across lines of therapy

Pirtobrutinib (Jaypirca) is a non-covalent Bruton tyrosine kinase (BTK) inhibitor. On 28 September 2026, Innovent Biologics announced that the NMPA had expanded the mainland China indication to monotherapy for adults with CLL/SLL across all lines of therapy, without a requirement for prior treatment with a covalent BTK inhibitor. The announcement covers the 50 mg and 100 mg tablets. Innovent states that Eli Lilly and Company developed pirtobrutinib and that Innovent commercialises it in mainland China.

"Across all lines of therapy" describes the scope of the regulatory label. It is not a statement that every adult with CLL/SLL should start with this medicine. A treatment decision still has to take in disease status, prior therapies, molecular features, comorbidities, drug interactions, current guidelines and the judgment of the treating specialist.

The announcement says the expansion was supported by the global phase 3 trials BRUIN CLL-313 and BRUIN CLL-314. In BRUIN CLL-313, the independent-review-committee assessment of progression-free survival for pirtobrutinib versus bendamustine plus rituximab was reported with a hazard ratio of 0.199. BRUIN CLL-314 met its primary endpoint of noninferiority for objective response rate, and the announcement reported a numerically higher response rate than ibrutinib. Its progression-free survival data were immature at the time of the announcement. A trend toward a progression-free survival benefit was reported. That trend should not be described as confirmed progression-free survival superiority.

This page does not establish whether pirtobrutinib is on the National Reimbursement Drug List, whether a given hospital stocks the tablets, or what a course will cost. Those are separate checks.

The 11.25 mg leuprorelin microsphere: a new strength, not a new molecule

On 30 September 2026, Livzon Pharmaceutical Group (丽珠医药集团; SZSE 000513) announced that its subsidiary Shanghai Livzon Pharmaceutical Co., Ltd. (上海丽珠制药有限公司) had received an NMPA supplementary-application approval notice, number 2026B06648. The notice agrees to add an 11.25 mg strength of leuprorelin acetate microspheres for injection (注射用醋酸亮丙瑞林微球). The approval number is 国药准字H20269239, valid to 27 April 2029. The marketing authorisation holder and the manufacturer named in the filing are both Shanghai Livzon Pharmaceutical Co., Ltd.

This is a long-acting administration option for an existing active substance, not the first approval of leuprorelin itself. The approved uses of the three-month strength are premenopausal breast cancer, prostate cancer and central precocious puberty. It is given by subcutaneous injection every 12 weeks.

The company states that the three-month strength differs from the already marketed 3.75 mg one-month strength in formulation process, quality standard, dose, administration and approved indications. A patient should not switch between those strengths, or between this microsphere and another leuprorelin product, without a clinician-directed assessment.

The same filing states that leuprorelin acetate microspheres for injection are a Class B item on the National Reimbursement Drug List (国家基本医疗保险、工伤保险和生育保险药品目录). That statement describes the product name. It does not tell an individual patient the copay, whether this new strength is stocked, or whether the local list has implemented the strength. The company also states that, excluding the originator, it is the only domestic holder of this three-month microsphere approval. Hospital formulary inclusion, procurement and the visit itself remain separate from that statement.

What a patient can confirm before travelling

Eligibility is a clinical decision. A family comparing headlines can still prepare the questions that decide whether a trip is even relevant:

1. The current prescribing information, not a news summary.
2. For satricabtagene autoleucel: documented CLDN18.2 status, HER2 status and the prior treatment lines.
3. For pirtobrutinib: a confirmed CLL/SLL diagnosis and the current treatment plan, including any previous BTK inhibitor.
4. For the leuprorelin microsphere: the exact indication, the strength, and whether a change from another formulation is being proposed.
5. Whether a specific hospital service can deliver that product, and a written estimate of the hospital's own charges.
6. How the original reports and images will be shared with the doctor at home.

Public, private or international hospital services in China explains why the service setting changes the appointment, the language of the report and the bill. Paying for healthcare and travel in China in 2026 separates hospital charges from everyday travel payments. Neither page prices these three medicines.

Where PriumCare fits in China

The part of this that is administrative, rather than clinical, is the part we can take on. Where that support is confirmed in your service scope, PriumCare can help organise records a hospital can read, request a consultation in an appropriate department, arrange language support, and collect the reports afterwards for the doctor at home. How PriumCare coordinates public-hospital care describes that coordination.

We do not diagnose, we do not treat, and we do not advise whether a named medicine is suitable. We do not sell, dispense or source prescription medicines. The hospital's physicians decide eligibility and any prescription. The hospital's own quote governs what you pay. PriumCare does not mark up hospital fees.

A news report is not a reason to start, stop or switch treatment. For a new, severe or worsening problem, call 120.

Frequently asked questions

Does NMPA approval mean that a therapy is widely accessible in mainland China?

No. NMPA approval authorises marketing within the approved label. It does not automatically decide National Reimbursement Drug List inclusion for every strength, local reimbursement, commercial insurance, hospital procurement, supply or treatment-service capacity. Each of those has to be checked on its own. For the leuprorelin microsphere, the manufacturer states that the product name is already a Class B listed item, and the practical copay and stock still have to be confirmed locally.

Does innovation drug access in China refer only to imported originator medicines?

No. These three decisions are different routes. Satricabtagene autoleucel is a domestically developed cell therapy reaching a solid-tumour approval. Pirtobrutinib is an internationally developed medicine whose China label was expanded, with commercialisation in mainland China by Innovent. The 11.25 mg leuprorelin microsphere is a locally manufactured long-acting strength of an established active substance. Import, local development and a new strength are not the same kind of access.

Is satricabtagene autoleucel approved for every gastric cancer?

No. The June 2026 label, as described by the Shanghai Science and Technology Commission, is limited to advanced gastric or gastroesophageal-junction adenocarcinoma that is CLDN18.2-positive and HER2-negative, after failure of at least second-line therapy. A gastric-cancer diagnosis on its own does not place a person inside that population.

Does "across all lines of therapy" mean pirtobrutinib is the right first treatment for every adult with CLL/SLL?

No. The phrase describes who the expanded label may cover. It does not rank the medicine against other options, and it does not replace specialist judgment. Prior treatment, molecular features, other illnesses and the current guideline still belong in the decision.

Can a patient switch from the 3.75 mg leuprorelin microsphere to the 11.25 mg strength without a new clinical decision?

No. The manufacturer states that the three-month strength differs in process, quality standard, dose, administration and indications from the 3.75 mg strength. Switching is a prescribing decision. It should not be made from a headline or from a wish to attend clinic less often.

How should a patient assess possible eligibility?

A relevant specialist should assess eligibility against the current prescribing information and the person's own record. Bring the biomarker results and prior treatments for the CAR-T, the diagnosis and treatment history for pirtobrutinib, and the indication plus the current formulation for leuprorelin. Ask the hospital whether it can provide that specific product and for a written estimate. Do not change treatment because of a news report.

Sources and scope

1. Satricabtagene autoleucel approval report, Shanghai Science and Technology Commission, 23 June 2026: https://stcsm.sh.gov.cn/xwzx/mtjj/20260623/b967b22329f24849949649988dd12897.html
2. Jaypirca CLL/SLL indication expansion, Innovent Biologics, 28 September 2026: https://en.prnasia.com/releases/global/jaypirca-pirtobrutinib-approved-in-china-for-a-new-indication-in-chronic-lymphocytic-leukemia-cll-small-lymphocytic-lymphoma-sll-across-all-lines-of-therapy-549764.shtml
3. Leuprorelin acetate microsphere 11.25 mg supplementary approval, Livzon Pharmaceutical Group, exchange announcement published 30 September 2026: https://vip.stock.finance.sina.com.cn/corp/view/vCB_AllBulletinDetail.php?id=12627011&stockid=000513
4. The same Livzon announcement as filed on the official disclosure platform: https://static.cninfo.com.cn/finalpage/2026-09-30/1225587853.PDF

This page is an industry and health-information reference as of 6 October 2026. It is not medical advice, prescribing guidance, investment advice or a reimbursement commitment. Product labels, prices, procurement, hospital availability and coverage should be rechecked against current authoritative sources at the point of use.

How to cite this page: China Medical Tour, "Innovation Drug Access in China: Three NMPA Approvals, Reviewed in October 2026", https://chinamedicaltour.org/library/articles/nmpa-innovation-drug-access-china-2026/, last reviewed 6 October 2026.